Sirion and Denali Collaborating to Develop Gene Therapies for Neurodegenerative Diseases

Sirion and Denali Collaborating to Develop Gene Therapies for Neurodegenerative Diseases
Sirion Biotech and Denali Therapeutics have agreed to partner on the development of gene therapies for Parkinson’s disease and other neurodegenerative disorders. According to the license and collaboration agreement, the two companies will pursue the development of harmless, next-generation adeno-associated viral vectors (AAV) able to cross the blood-brain barrier — a semipermeable membrane that protects the brain against the external environment. Besides Parkinson’s, ... read more
Source: Parkinson’s News TodayPublished on 2019-01-14By Jose Marques Lopes, PhD